
Hematologic Oncology
Latest News
Latest Videos

Podcasts
CME Content
More News

Data from the phase 1/2 CADENZA trial support the approval of pivekimab sunirine for patients with blastic plasmacytoid dendritic cell neoplasms.

Mitchell E. Horwitz, MD, discussed how omidubicel and other advances in allogeneic transplantation have affected different hematologic oncology populations.

Investigators evaluated how tisagenlecleucel and cilta-cel altered adverse effect timelines for patients treated for hematologic malignancies.

Experts highlight advances in cellular therapies that were discussed at the 2026 National ICE-T Conference in Charlotte, North Carolina.

Ralph V. Boccia, MD, FACP, discussed the operational hurdles of administering bispecific antibodies in community settings.

Novel bispecifics may bridge gaps in care, especially among patients in rural settings, according to Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA.

Researchers have reported that CD7 may be a viable CAR T-cell target in a subset of relapsed/refractory acute myeloid leukemia, and that fratricide-resistant CD7 CAR T cells can induce deep remissions with an encouraging early safety profile.

Researchers have demonstrated that BET inhibition can reverse key immunologic and fibrotic features of bronchiolitis obliterans syndrome, a severe pulmonary form of chronic GVHD.

The RUBY trial demonstrates that disrupting the BCL11A binding site in the γ-globin promoters can normalize hemoglobin in severe sickle cell disease.

The FDA has extended the PDUFA action date to July 6, 2026, for approving Orca-T across different hematologic malignancies.

The real-world CHRONOS study may set a new benchmark for the third-line management of acute graft-vs-host-disease with gastrointestinal involvement.

A landmark Nature study demonstrates targeted CRISPR-based CAR transgene integration in living patients' T cells without ex vivo manufacturing.

An intern doctor at Al-Sabah Children’s Hospital sheds light on health care delivery gaps in a resource-limited setting.

Maintaining quality of life should be a key focus in the treatment of different hematologic malignancy populations, explained Guenther Koehne, MD.

Treatment with rusfertide appears to reliably control hematocrit among those with polycythemia vera, according to Andrew Kuykendall, MD.

Yan Leyfman, MD, discussed the factors that may ultimately define the next era of transplant medicine across hematologic malignancies.

The FDA has set a Prescription Drug User Fee Act date for the third quarter of 2026 for approving rusfertide for polycythemia vera.

Yan Leyfman, MD, reviewed how toxicity management in hematologic oncology is shifting to phenotype- and mechanism-informed intervention.

































































